<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">ZOLEDRONIC ACID</span><br/>(zo-le-dron'ic)<br/><span class="topboxtradename">Zometa<br/></span><b>Classifications:</b> <span class="classification">bisphosphonate</span>; <span class="classification">regulator, bone metabolism</span><br/><b>Prototype: </b>Etidronate Disodium<br/><b>Pregnancy Category: </b>D<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>4 mg vial</p>
<h1><a name="action">Actions</a></h1>
<p>Zoledronic acid inhibits bone resorption by inhibiting osteoclastic activity and inducing osteoclast apoptosis. Zoledronic
         acid also blocks osteoclastic resorption of bone and cartilage. It inhibits various stimulatory factors of osteoclastic activity
         by bone tumors.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Zoledronic acid inhibits osteoclastic activity and sketetal calcium release induced by various stimulatory factors released
         by bone tumors.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of hypercalcemia of malignancy, multiple myeloma, and bony metastases from solid tumors.</p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Paget's disease.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to zoledronic acid or other bisphosphonates; preexisting hypocalcemia; serum creatinine of 0.5 mg/dL; pregnancy
         (category D).
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Lactation, renal, and/or hepatic impairment; dental work; concurrent administration of aminoglycosides, or loop diuretics;
         older adults. Safety and effectiveness of zoledronic acid in pediatric patients have not been established.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Hypercalcemia of Malignancy</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 4 mg over a minimum of 15 min. May consider retreatment if serum calcium has not returned to normal, may repeat after 7 d<br/><br/><span class="indicationtitle">Multiple Myeloma and Bony Metastases from Solid Tumors</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 4 mg over a minimum of 15 min q 34 wk<br/><br/><span class="indicationtitle">Paget's Disease</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> A single dose of 200 mcg or 400 mcg<br/><br/><span class="impairmenttitle">Renal Impairment</span><br/>Dose in renal insufficiency: Cl<sub>cr</sub> &gt;60 mL/min = 4 mg; Cl<sub>cr</sub> 5060 mL/min = 3.5 mg; Cl<sub>cr</sub> 4049 mL/min = 3.3 mg; Cl<sub>cr</sub> 3039 mL/min = 3.0 mg<br/><br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><ul>
<li>Do not administer to anyone who is dehydrated or suspected of being dehydrated. Consult physician.</li>
<li>Do not administer zoledronic acid unless patient is adequately rehydrated.</li>
<li>Do not administer until serum creatinine values have been evaluated by the physician.</li>
</ul>
<p><span class="routemethod">PREPARE:</span> <span class="methodtype">IV Infusion:</span> Reconstitute by adding 5 mL of sterile water for injection to each vial. Withdraw the entire contents of the vial (4 mg) and
                  further dilute in 100 mL of D5W or NS. Do not use Lactated Ringer's solution. If not used immediately, refrigerate. The total
                  time between reconstitution and end of infusion must not exceed 24 h.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">IV Infusion:</span> Infuse 4 mg or less (NEVER MORE) over NO LESS than 15 min.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype">Solution/additive and Y-site:</span> Do not mix or infuse with <b>calcium</b>-containing solutions (e.g., <b>Ringer's Lactate</b>). 
               </p>
</td>
</tr>
</table>
<ul>
<li>Store at 2°8° C (36°46° F) follow reconstitution. Must be completely infused within 24 h of
            reconstitution.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> Body as a Whole:</span>
<span class="speceff-common">Fever,</span> flu-like syndrome, redness and swelling at injection site, asthenia, chest apin, leg edema, mucositis, rigors. <span class="typehead">CNS:</span>
<span class="speceff-common">Insomnia, anxiety, confusion, agitation,</span> headache, somnolence. <span class="typehead">CV:</span>
<span class="speceff-common">Hypotension</span>. <span class="typehead">GI:</span>
<span class="speceff-common">Nausea, vomiting, constipation, abdominal pain, anorexia,</span> dysphagia. <span class="typehead">Hematologic:</span>
<span class="speceff-common">Anemia,</span> granulocytopenia, thrombocytopenia, <span class="speceff-life">pancytopenia</span>. <span class="typehead">Metabolic:</span>
<span class="speceff-common">Hypophosphatemia, hypokalemia, hypomagnesemia,</span> hypocalcemia, dehydration. <span class="typehead">Musculoskeletal:</span> Skeletal pain, arthralgias, osteonecrosis of the jaw in cancer patients.  <span class="typehead">Respiratory:</span>
<span class="speceff-common">Dyspnea, cough,</span> pleural effusion. <span class="typehead">Skin:</span> Alopecia, dermatitis. <span class="typehead">Urogenital:</span> Renal deterioration [increase in serum creatinine (SCr)]. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<span class="classification">loop diuretics</span> may increase risk of hypocalcemia; <b>thalidomide</b> and other <span class="classification">nephrotoxic drugs</span> may increase risk of renal toxicity. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Onset:</span> 410 d. <span class="typehead">Duration:</span> 34 wk. <span class="typehead">Metabolism:</span> Not metabolized. <span class="typehead">Elimination:</span> Excreted in urine. <span class="typehead">Half-Life:</span> 146 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Baseline renal function tests prior to each dose and periodically thereafter; periodic ionized calcium or corrected
            serum calcium (CSC) levels, serum phosphate and magnesium, electrolytes, CBC with differential, Hct and Hgb.
         </li>
<li>Notify physician immediately of deteriorating renal function as indicated by rising serum creatinine levels over baseline
            value.
         </li>
<li>Withhold subsequent doses of zoledronic acid if serum creatinine is not within 10% of the baseline value. Consult physician.</li>
<li>Monitor closely patient's hydration status. Note that loop diuretics should be used with caution due to the risk of hypocalcemia.</li>
<li>Monitor for S&amp;S of bronchospasm in aspirin-sensitive asthma patients; notify physician immediately.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Maintain adequate daily fluid intake. Consult with physician for guidelines.</li>
<li>Report unexplained weakness, tiredness, irritation, muscle pain, insomnia, or flu-like symptoms.</li>
<li>Do not breast feed without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>